BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 27835609)

  • 1. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
    Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
    Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma.
    Gómez-Rodríguez R; Romero-Gutiérrez M; Artaza-Varasa T; González-Frutos C; Ciampi-Dopazo JJ; de-la-Cruz-Pérez G; Sánchez-Ruano JJ
    Rev Esp Enferm Dig; 2012 Jun; 104(6):298-304. PubMed ID: 22738699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
    Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma.
    Farinati F; Vitale A; Spolverato G; Pawlik TM; Huo TL; Lee YH; Frigo AC; Giacomin A; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Biasini E; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Masotto A; Trevisani F; Cillo U;
    PLoS Med; 2016 Apr; 13(4):e1002006. PubMed ID: 27116206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
    Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
    Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.
    Zhang XF; Qi X; Meng B; Liu C; Yu L; Wang B; Lv Y
    Eur J Surg Oncol; 2010 Aug; 36(8):718-24. PubMed ID: 20538423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
    Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
    World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.
    Liu C; Xiao GQ; Yan LN; Li B; Jiang L; Wen TF; Wang WT; Xu MQ; Yang JY
    World J Gastroenterol; 2013 Mar; 19(11):1811-9. PubMed ID: 23555170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
    Adhoute X; Pénaranda G; Raoul JL; Blanc JF; Edeline J; Conroy G; Perrier H; Pol B; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Bronowicki JP; Bourlière M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):433-40. PubMed ID: 26695429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients.
    Burnett NP; Dunki-Jacobs EM; Callender GG; Anderson RJ; Scoggins CR; McMasters KM; Martin RC
    Am Surg; 2013 Jul; 79(7):716-22. PubMed ID: 23816006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.
    Jitpraphawan O; Ruamtawee W; Treewatchareekorn M; Sethasine S
    World J Gastroenterol; 2024 May; 30(17):2343-2353. PubMed ID: 38813057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening.
    Tseng PL; Wang JH; Tung HD; Hung CH; Kee KM; Chen CH; Chang KC; Lee CM; Changchien CS; Chen PF; Tsai LS; Lu SN
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1426-34. PubMed ID: 20659234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
    Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
    Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
    Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection.
    Lin K; Huang Q; Zeng J; Ding Z; Wang L; Chen Z; Guo P; Zeng Y; Zhou W; Liu J
    Dig Dis Sci; 2021 Dec; 66(12):4545-4556. PubMed ID: 33723698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.